Comparative Pharmacology
Head-to-head clinical analysis: ANCOBON versus NYSERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCOBON versus NYSERT.
ANCOBON vs NYSERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.
NYSERT is a fixed-dose combination of nystatin and sertaconazole. Nystatin, a polyene antifungal, binds to ergosterol in fungal cell membranes, disrupting permeability and causing cell death. Sertaconazole, an azole antifungal, inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis and accumulation of toxic methylsterols. Synergistic action provides broad-spectrum antifungal activity against Candida spp. and dermatophytes.
50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.
10 mg orally once daily at bedtime, with or without food.
None Documented
None Documented
Terminal elimination half-life 2.5-6 hours (normal renal function). Prolonged to 30-250 hours in renal impairment (CrCl < 20 mL/min). Half-life correlates with creatinine clearance.
Terminal elimination half-life approximately 20-25 hours in healthy adults; prolonged in hepatic impairment (up to 40 hours) and in elderly patients.
Primarily renal excretion of unchanged drug (75-90% within 24 hours). Less than 1% eliminated as 5-fluorouracil metabolite. Biliary/fecal excretion negligible.
Primarily hepatic metabolism (CYP3A4) followed by biliary excretion of metabolites; ~60% fecal, ~30% renal (as metabolites), <5% unchanged in urine.
Category C
Category C
Antifungal
Antifungal